13,667 Shares in Zimmer Biomet Holdings Inc (ZBH) Purchased by Belpointe Asset Management LLC
Belpointe Asset Management LLC bought a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,667 shares of the medical equipment provider’s stock, valued at approximately $1,600,000.
Several other hedge funds have also bought and sold shares of ZBH. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Zimmer Biomet by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares in the last quarter. Bank of Nova Scotia Trust Co. bought a new stake in Zimmer Biomet in the third quarter worth $112,000. FNY Managed Accounts LLC bought a new stake in Zimmer Biomet in the third quarter worth $117,000. BB&T Investment Services Inc. bought a new stake in Zimmer Biomet in the second quarter worth $144,000. Finally, Sandy Spring Bank lifted its position in Zimmer Biomet by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 66 shares during the last quarter. 86.24% of the stock is owned by hedge funds and other institutional investors.
ZBH has been the subject of a number of analyst reports. Gabelli initiated coverage on Zimmer Biomet in a research report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price target for the company. Zacks Investment Research upgraded Zimmer Biomet from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. SunTrust Banks restated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research report on Monday, October 2nd. Piper Jaffray Companies downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 2nd. Finally, BMO Capital Markets lowered their price target on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, November 2nd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $134.05.
Zimmer Biomet Holdings Inc (NYSE:ZBH) traded up $0.03 during trading hours on Wednesday, hitting $113.54. The stock had a trading volume of 1,594,400 shares, compared to its average volume of 1,356,405. Zimmer Biomet Holdings Inc has a fifty-two week low of $100.81 and a fifty-two week high of $133.49. The company has a market capitalization of $22,982.72, a P/E ratio of 14.07, a price-to-earnings-growth ratio of 1.76 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter last year, the business posted $1.79 earnings per share. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. analysts forecast that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current fiscal year.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with Analyst Ratings Network's FREE daily email newsletter.